ARISTO — Aristo Bio-Tech and Lifescience Income Statement

0.000.00%

Last trade - 00:00

Basic MaterialsHighly SpeculativeMicro CapTurnaround

Annual income statement for Aristo Bio-Tech and Lifescience, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2019 March 31st	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	PROSPECTUS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,017	2,012	1,672	1,660	2,179
Cost of Revenue
Gross Profit	175	137	172	189	221
Selling / General / Administrative Expenses
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	1,954	1,972	1,636	1,616	2,107
Operating Profit	62.5	39.9	35.9	43.6	71.7
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	41	14	15	20.4	47.4
Provision for Income Taxes
Net Income After Taxes	28.3	10.1	10.8	14.5	35.6
Net Income Before Extraordinary Items
Net Income	28.3	10.1	10.8	14.5	35.6
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	28.3	10.1	10.8	14.5	35.6
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	4.15	1.48	1.58	2.11	5.23
Dividends per Share